ICU Medical (ICUI) Fundamental Analysis: Revenue, Earnings & Valuation

6.67 / 10

Outperform

Fundamental analysis rates ICUI as Outperform, scoring 6.67/10. Key strengths are profit‑to‑market and cash‑to‑market ratios, while revenue‑to‑market lags. Overall metrics suggest solid profitability and asset quality despite modest revenue concerns.

Analysis Checks(9/10)

Revenue-MV

Value0.27

Score1/3

Weight-8.55%

1M Return-0.97%

ROA (%)

Value0.02

Score2/3

Weight6.20%

1M Return0.64%

Net cash flow from operating activities / Operating revenue (%)

Value8.06

Score3/3

Weight17.05%

1M Return1.63%

Profit-MV

Value-4.67

Score2/3

Weight31.78%

1M Return3.09%

Annualized net profit margin on total assets (%)

Value0.02

Score2/3

Weight6.20%

1M Return0.64%

EBIT / Total operating revenue (%)

Value3.86

Score2/3

Weight0.95%

1M Return0.10%

Asset-MV

Value-0.55

Score2/3

Weight5.44%

1M Return0.57%

Net profit / Total operating revenue (%)

Value0.03

Score3/3

Weight14.15%

1M Return1.41%

Cash-MV

Value-0.46

Score3/3

Weight31.71%

1M Return2.92%

Net profit / Total profit (%)

Value23.10

Score2/3

Weight-4.92%

1M Return-0.54%

Is ICUI undervalued or overvalued?

ICUI scores 6.67/10 on fundamentals and holds a Discounted valuation at present. Backed by its 0.04% ROE, 0.03% net margin, 4284.54 P/E ratio, 1.48 P/B ratio, and 100.62% earnings growth, these metrics solidify its Outperform investment rating.